Ashion Analytics GEMExTra test detects rare NRG1 gene fusions in patients whose cancer is driven by this genomic alteration for potential matching to a clinical trial
New PATRIOT analysis unveiled at this week’s AACR meeting; builds on Ashion’s GEM-ExTra program, providing unprecedented accuracy in prescribing anti-cancer treatments